NY-ESO-1 is an important member of cancer-testis antigen family and is widely distributed among many cancer types. As a tumor-specific antigen with the strongest immunogenicity so far identified, it can induce spontaneous antibody and T-cell responses in patients with NY-ESO-1-positive tumors. Therefore, it has been a good vaccine candidate in the immunotherapy against many malignancies. This article reviews the recent research advances in NY-ESO-1 and its relevant vaccines.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
[ny-eso-1 cancer
4
cancer immunotherapy]
4
immunotherapy] ny-eso-1
4
ny-eso-1 member
4
member cancer-testis
4
cancer-testis antigen
4
antigen family
4
family distributed
4
distributed cancer
4
cancer types
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!